Prompted by the highly prevalent loss of NMT2 expression in various cancers (Fig. 1), especially in hematologic cancers, we sought to target the remaining NMT1 with the potent pan-NMT inhibitor PCLX-001 in a manner reminiscent of synthetic lethality, thereby sparing normal cells with two NMTs. Here, NMT2 is linked to hematopoietic and lymphoid cell neoplasm.